- Home
- KAI vs DNLI Comparison
KAI vs DNLI Comparison
Compare KAI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAI | DNLI |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KAI | DNLI |
|---|---|---|
| Price | $316.24 | $25.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $337.50 | $34.33 |
| AVG Volume (30 Days) | 163.2K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $1,052,248,000.00 | N/A |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $4.87 | $408.85 |
| P/E Ratio | $145.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $244.87 | $12.58 |
| 52 Week High | $369.97 | $26.19 |
Technical Indicators
Market Signals| Indicator | KAI | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 77.22 |
| Support Level | $283.06 | $18.27 |
| Resistance Level | $335.01 | N/A |
| Average True Range (ATR) | 11.20 | 1.20 |
| MACD | 3.20 | 0.37 |
| Stochastic Oscillator | 78.35 | 95.08 |
Price Performance
Historical ComparisonAbout KAI Kadant Inc
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.